Overview

Phase II Study of Cobimetinib in Combination With Vemurafenib in Active Melanoma Brain Metastases

Status:
Terminated
Trial end date:
2016-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effectiveness of the combination of vemurafenib with cobimetinib in patients with active melanoma brain metastases.
Phase:
Phase 2
Details
Lead Sponsor:
Melissa Burgess, MD
Collaborator:
Genentech, Inc.
Treatments:
Vemurafenib